Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Rajiv Anand, David Birch, Darin Curtiss, Alessandro Iannaccone, Jung Ah Jung, Andreas Lauer, Mark E Pennesi, Abraham Scaria, Robert Sisk, Nadia K Waheed, Antonio Yaghy, Paul Yang

Ngôn ngữ: eng

Ký hiệu phân loại: 615.895 Gene therapy

Thông tin xuất bản: United States : American journal of ophthalmology , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 89741

PURPOSE: To evaluate the safety and efficacy of subretinal gene therapy using AGTC-501 (rAAV2tYF-GRK1-RPGR) in male participants with X-linked retinitis pigmentosa (XLRP). DESIGN: Phase 1/2, open-label, dose-escalation study. METHODS: Setting: Four centers in the United States. Patient or Study Population: Twenty-nine males with XLRP and confirmed pathogenic RPGR variants. Mean age was 31.6 years (range 15-55). INTERVENTION: Subretinal injection of AGTC-501 at doses ranging from 2.48 × 10 MAIN OUTCOME MEASURES: Treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), laboratory parameters, and immunological responses. Efficacy was evaluated by mesopic microperimetry mean sensitivity. RESULTS: All 29 participants experienced ≥1 TEAE. Eleven (38%) experienced ≥1 grade 3 TEAE. Six (21%) experienced ≥1 ocular SAE related to AGTC-501, including retinal detachment (n = 4), subcapsular cataract (n = 1), and glaucoma (n = 1). Two (6.9%) experienced non-ocular treatment-emergent SAEs. Immunological findings did not indicate safety concerns. Three of 4 participants at the highest dose exhibited concerning retinal pigment epithelial changes. Half the participants at the highest tolerated dose (6.8 × 10 CONCLUSIONS: Subretinal AGTC-501 was generally well-tolerated. Despite all participants experiencing at least one TEAE, most of these events were mild in nature, exhibited complete resolution, and were associated with the subretinal injection procedure itself rather than the study agent. The highest dose exhibited an unfavorable risk-benefit profile due to the development of RPE changes. Although this group had the highest improvement in retinal sensitivity, our team has decided not to continue this dose in future clinical trials. Preliminary efficacy was observed at the maximum tolerated dose. Further studies are warranted to assess long-term safety and efficacy of AGTC-501 for XLRP treatment.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH